TPTX » Topics » Consolidated Statements of Operations

This excerpt taken from the TPTX DEF 14A filed Jun 19, 2009.

Consolidated Statements of Operations

(in thousands, except share and per share data)

(Unaudited)

 

     Three months ended
March 31,
 
     2009     2008  

Revenue

    

License and option fees

   $ —       $ 1,283  

Research funding

     —         763  
                

Total revenue

     —         2,046  

Operating expenses

    

Research and development

     855       5,260  

General and administrative

     1,268       1,448  
                

Total operating expenses

     2,123       6,708  

Loss from operations

     (2,123 )     (4,662 )

Other income (expense)

    

Interest income

     8       217  

Interest expense

     (45 )     (147 )

Other income (expense), net

     40       699  
                

Total other income (expense)

     3       769  
                

Net loss

     (2,120 )     (3,893 )
                

Basic and diluted net loss per share

   $ (0.13 )   $ (0.25 )
                

Weighted average shares used in the computation of basic and diluted net loss per share

     15,974,058       15,739,646  
                

See accompanying notes.

 

2


Table of Contents

TorreyPines Therapeutics, Inc.

This excerpt taken from the TPTX 10-Q filed May 1, 2009.

Consolidated Statements of Operations

(in thousands, except share and per share data)

(Unaudited)

 

     Three months ended
March 31,
 
     2009     2008  

Revenue

    

License and option fees

   $ —       $ 1,283  

Research funding

     —         763  
                

Total revenue

     —         2,046  

Operating expenses

    

Research and development

     855       5,260  

General and administrative

     1,268       1,448  
                

Total operating expenses

     2,123       6,708  

Loss from operations

     (2,123 )     (4,662 )

Other income (expense)

    

Interest income

     8       217  

Interest expense

     (45 )     (147 )

Other income (expense), net

     40       699  
                

Total other income (expense)

     3       769  
                

Net loss

     (2,120 )     (3,893 )
                

Basic and diluted net loss per share

   $ (0.13 )   $ (0.25 )
                

Weighted average shares used in the computation of basic and diluted net loss per share

     15,974,058       15,739,646  
                

See accompanying notes.

 

2


Table of Contents

RELATED TOPICS for TPTX:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki